📰 Sight Biologic News
Page 2 - Sight Biologic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sight Biologic. Real-time updates on events, politics, business and more.
May 1, 2023
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative
April 20, 2023
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for
April 20, 2023
Press Release GenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business Update EMA oral presentation... | April 20, 2023
April 4, 2023
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for
March 24, 2023
Efforts to reduce cash burn in 2023 while securing LUMEVOQ manufacturing and preparing for commercial launch in Europe in H1 2024 PPQ campaign to start early May 2023 with results expected
March 13, 2023
Sustained efficacy three years after injection: statistically significant visual acuity improvement from nadir Continuous benefits in bilaterally treated patients with +17 to +20 ETDRS letters
March 7, 2023
PPQ campaign to start early May 2023 (previously end of March) with results expected in Q3 2023 EMA CHMP opinion now expected in Q1 2024 (previously September 2023) Regulatory News: GenSight
February 28, 2023
Leber Hereditary Optic Neuropathy (LHON) is a rare disease predominantly affecting people aged 15 to 35 year that causes irreversible and severe vision loss, resulting in blindness Patients
February 6, 2023
Proceeds intended to support the development of GenSight Biologics' product portfolio, including the preparation of the LUMEVOQ European launch expected by the end of 2023 Regulatory News: GenSight
January 4, 2023
04.01.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system ...